Evolutionary Genomics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FNAM research report →
Price Chart
About the company
Evolutionary Genomics, Inc. , together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. The company develops Adapted Traits Platform, a technology platform to identify genes for enhancing crop plant traits, such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance.
- CEO
- Steven Bryan Warnecke
- IPO
- 2011
- Employees
- 2
- HQ
- Castle Rock, CO, US
Get TickerSpark's AI analysis on FNAM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.33K
- P/E
- -0.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -3.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 64.84%
- ROIC
- -92.59%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-1,021,493+1.7%
- Op Income
- $-2,014,302
- Net Income
- $-1,934,967+30.7%
- EPS
- $-0.35+32.7%
- OCF Growth
- +59.5%
- FCF Growth
- +59.5%
- 52W High
- $0.45
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.12
- RSI (14)
- 0
- Avg Volume
- 277
No earnings-call transcripts are available for FNAM yet.
- Free Float
- 67.4%
- Shares Outstanding
- 6.66M
- Float Shares
- 4.48M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 23, 22 | Messier Walter | other | 78,571 |
| May 23, 22 | Messier Walter | other | 100,000 |
| May 23, 22 | WARNECKE STEVE B | other | 66,667 |
| May 23, 22 | WARNECKE STEVE B | other | 52,381 |
| May 23, 22 | WARNECKE STEVE B | other | 66,667 |
| May 23, 22 | WARNECKE STEVE B | other | 66,667 |
| May 23, 22 | Orndorff Virginia P. | other | 20,000 |
| May 23, 22 | Orndorff Virginia P. | other | 15,714 |
| May 23, 22 | Orndorff Virginia P. | other | 20,000 |
| May 23, 22 | Orndorff Virginia P. | other | 20,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our FNAM coverage
Recent articles, reports, and earnings notes.
No research on FNAM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate FNAM report →